Genitourinary Oncology Program, Texas Oncology, PA, US Oncology Research, 501 Medical Center Blvd, Webster, TX 77598, USA

This email address is being protected from spam bots, you need Javascript enabled to view it

The recent approvals of sunitinib, sorafenib and temsirolimus have revolutionized the management of renal cell carcinoma (RCC). Pazopanib (GW-786034) is a second-generation multitargeted tyrosine kinase inhibitor against VEGFR-1, 2 and 3, platelet-derived growth factor receptor (PDGFR)-alpha, PDGFR-beta and c-kit.

Data supporting the development of pazopanib for RCC are reviewed.

Preclinical and clinical data available for pazopanib are presented

Preclinical evaluation has revealed excellent anti-angiogenic and anti-tumor activity in several mouse models. A Phase II clinical trial of pazopanib in untreated or cytokine/bevacizumab pretreated RCC has demonstrated promising activity accompanied by a favorable toxicity profile. A placebo-controlled Phase III trial is ongoing in untreated or cytokine-treated patients with RCC. Ongoing trials are further evaluating pazopanib in a variety of other malignancies.

Written by
Sonpavde G, Hutson TE, Sternberg CN.

Reference
Expert Opin Investig Drugs. 2008 Feb;17(2):253-61
doi:10.1517/13543784.17.2.253

PubMed Abstract
PMID:18230058

UroToday.com Renal Cancer Section

Please log-in or register in order to submit comments.

Powered by AkoComment!